血管內皮生長因子受體2(VEGFR2)活性蛋白
Active Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
CD309; FLK1; VEGFR; KDR; A Type III Receptor Tyrosine Kinase; Kinase Insert Domain Receptor; Kinase Insert Domain Receptor; Fetal Liver Kinase-1
- 編號APB367Hu61
- 物種Homo sapiens (Human,人) 相同的名稱,不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 97%
- 等電點6.5
- 應用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1296 ¥ 3240 ¥ 6480 ¥ 19440 ¥ 48600
- 欲了解實際交易價格和更多情況,請與當?shù)亟?jīng)銷商聯(lián)系!
活性實驗
Figure. Cell proliferation of ECV-304 cells inhibit by VEGFR2.
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) also known as kinase insert domain receptor acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. VEGFR2 functions as the primary mediator of vascular endothelial growth factor activation in endothelial cells. Regulation of VEGFR-2 expression appears critical in mitogenesis, differentiation, and angiogenesis. To test the effect on inhibit the VEGF-dependent proliferation of endothelium cells, ECV-304 cells were seeded into triplicate wells of 96-well plates at a density of 5,000 cells/well and allowed to attach, replaced with serum-free overnight, then the medium was replaced with 2% serum standard DMEM?including 1μg/mL Vascular Endothelial Growth Factor C (VEGFC) and various concentrations of recombinant human VEGFR2. After incubated for 96h,?cells were observed by inverted microscope and cell proliferation was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10μL of CCK-8 solution was added to each well of the plate, then the absorbance at 450nm was measured using a microplate reader after incubating the plate for 1-4 hours at 37℃. Proliferation of ECV-304 cells after incubation with VEGFR2 for 96h observed by inverted microscope was shown in Figure 1. Cell viability was assessed by CCK-8 (Cell Counting Kit-8) assay after incubation with recombinant VEGFR2 for 96h. The result was shown in Figure 2. It was obvious that VEGFR2 significantly inhibit cell viability of ECV-304.
(A) ECV-304 cells cultured in DMEM, stimulated with 10ng/mL VEGFR2 for 96h;
(B) Unstimulated ECV-304 cells cultured in DMEM for 96h.
Figure. VEGFR2 inhibit VEGF-dependent proliferation of ECV-304 cells.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月,-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定,具體方法如下:在37°C孵育48小時,沒有顯著的降解或者沉淀產生。保質期內,在適當?shù)臈l件下存儲,損失率低于5%。
增值服務
相關產品
編號 | 適用物種:Homo sapiens (Human,人) | 應用(僅供研究使用,不用于臨床診斷!) |
APB367Hu61 | 血管內皮生長因子受體2(VEGFR2)活性蛋白 | Cell?culture;?Activity?Assays. |
EPB367Hu61 | 血管內皮生長因子受體2(VEGFR2)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APB367Hu01 | 血管內皮生長因子受體2(VEGFR2)活性蛋白 | Cell?culture;?Activity?Assays. |
RPB367Hu01 | 血管內皮生長因子受體2(VEGFR2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB367Hu01 | 血管內皮生長因子受體2(VEGFR2)多克隆抗體 | WB; IHC; ICC; IP. |
LAB367Hu81 | 血管內皮生長因子受體2(VEGFR2)多克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
LAB367Hu71 | 血管內皮生長因子受體2(VEGFR2)多克隆抗體(生物素標記) | WB; IHC; ICC. |
FAB367Hu51 | 抗血管內皮生長因子受體2(VEGFR2)多克隆抗體(別藻藍蛋白標記) | FCM |
MAB367Hu23 | 血管內皮生長因子受體2(VEGFR2)單克隆抗體 | WB; IHC; ICC; IP. |
MAB367Hu26 | 血管內皮生長因子受體2(VEGFR2)單克隆抗體 | WB; IHC; ICC; IP. |
RAB367Hu21 | 血管內皮生長因子受體2(VEGFR2)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
MAB367Hu22 | 血管內皮生長因子受體2(VEGFR2)單克隆抗體 | WB; IHC; ICC; IP. |
MAB367Hu24 | 血管內皮生長因子受體2(VEGFR2)單克隆抗體 | WB; IHC; ICC; IP. |
MAB367Hu21 | 血管內皮生長因子受體2(VEGFR2)單克隆抗體 | WB; IHC; ICC; IP. |
FAB367Hu32 | 抗血管內皮生長因子受體2(VEGFR2)單克隆抗體(別藻藍蛋白/花青染料cy7標記) | FCM |
FAB367Hu82 | 抗血管內皮生長因子受體2(VEGFR2)單克隆抗體(異硫氰酸熒光素標記) | Flow cytometry. |
HEB367Hu | 血管內皮生長因子受體2(VEGFR2)檢測試劑盒(酶聯(lián)免疫吸附試驗法,高敏型) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SEB367Hu | 血管內皮生長因子受體2(VEGFR2)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB367Hu | 血管內皮生長因子受體2(VEGFR2)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
KSB367Hu01 | 血管內皮生長因子受體2(VEGFR2)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | 自己動手制作ELISA試劑盒的主要材料 |
參考文獻
雜志 | 參考文獻 |
APMIS | Peritumoral brain edema in angiomatous supratentorial meningiomas: an investigation of the vascular endothelial growth factor A pathway [PubMed: 23398358] |
Acta Biomater | Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: an in vitro osteoblast-osteoclast-endothelial cell co-culture study [PubMed: 26689470] |
Acta Biomaterialia | Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: An in vitro osteoblast–osteoclast–endothelial cell co-culture study [Pubmed:26689470] |
Journal?of?Cellular?Physiology | A?Human?3D?In?Vitro?Model?to?Assess?the?Relationship?Between?Osteoporosis?and?Disseminationto?Bone?of?Breast?Cancer?Tumor?Cells. [pubmed:27925188] |
Regenerative Biomaterials | The directional migration and differentiation of mesenchymal stem cells toward vascular endothelial cells stimulated by biphasic calcium phosphate ceramic [10.1093/rb/rbx028] |
International Journal of Immunopathology and Pharmacology | VEGF-R2 and TNF-R1 expression and cytokine production by samples of mammary adenocarcinomas and correlations with histopathological parameters of these?… [Pubmed:29985074] |
JOURNAL OF DERMATOLOGICAL TREATMENT | Effect of isotretinoin (13-cis-retinoic acid) on levels of soluble VEGF receptors (sVEGFR1, sVEGFR2, sVEGFR3) in patients with acne vulgaris [Pubmed: 32043381] |
Journal of Genetic Engineering and Biotechnology | Encapsulated VEGF 121-PLA microparticles promote angiogenesis in human endometrium stromal cells [33523322] |
Mol Cell Biochem | Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy [34324118] |
BMC Nephrol | Effect of subacute poisoning with lambdacyhalothrin on vascular endothelial growth factor 2 receptor in mice kidneys [Pubmed:35643467] |